Improving Utilization of SGLT2 Inhibitors in the Inpatient Setting

SGLT2 inhibitors have been shown to have a significant benefit for patients with DM2 or CAD (DAPA-HF, Emperor-reduced) The usage of these medications are low compared to other Goal Directed Medical Therapy. There are multiple contributing factors as to why these medications are underutilized Our aim is to assess barriers against prescription of SGLT2-i at the time of discharge from TJUH and to increase utilization after placement on formulary

Measurement of insulin and other glucose-regulating peptide hormones.

Insulin activity is an important laboratory parameter in the clinical evaluation of several diseases such as diabetes mellitus types I and II, states of impaired glucose tolerance, and insulin-producing tumors (insulinomas), where the insulin secretion released from pancreas β-cells is altered